## J Leinonen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10888025/publications.pdf

Version: 2024-02-01

331670 395702 2,504 34 21 33 citations h-index g-index papers 35 35 35 1405 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	First observations of tripleâ€frequency radar Doppler spectra in snowfall: Interpretation and applications. Geophysical Research Letters, 2016, 43, 2225-2233.	4.0	48
2	Performance assessment of a triple-frequency spaceborne cloud–precipitation radar concept using a global cloud-resolving model. Atmospheric Measurement Techniques, 2015, 8, 3493-3517.	3.1	18
3	What do tripleâ€frequency radar signatures reveal about aggregate snowflakes?. Journal of Geophysical Research D: Atmospheres, 2015, 120, 229-239.	3.3	58
4	Linking snowflake microstructure to multiâ€frequency radar observations. Journal of Geophysical Research D: Atmospheres, 2013, 118, 3259-3270.	3.3	29
5	Evidence of nonspheroidal behavior in millimeterâ€wavelength radar observations of snowfall. Journal of Geophysical Research, 2012, 117, .	3.3	62
6	VALIDITY OF THE PROSTATE SPECIFIC ANTIGEN TEST FOR PROSTATE CANCER SCREENING: FOLLOWUP STUDY WITH A BANK OF 21,000 SERA IN FINLAND. Journal of Urology, 2001, 166, 2189-2192.	0.4	50
7	Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. FEBS Journal, 2000, 267, 6212-6220.	0.2	69
8	Reduced Stability of Prostate-Specific Antigen after Long-Term Storage of Serum at –20°C. Tumor Biology, 2000, 21, 46-53.	1.8	8
9	Determination of prostate-specific antigen complexed to alpha2-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology, 2000, 56, 267-272.	1.0	42
10	Prostate-specific antigen and other prostate cancer markers. Urology, 2000, 56, 893-898.	1.0	31
11	Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement, 2000, 233, 59-64.	2.7	1
12	Reactivity of 77 Antibodies to Prostate-Specific Antigen with Isoenzymes and Complexes of Prostate-Specific Antigen. Tumor Biology, 1999, 20, 28-34.	1.8	11
13	Reactivity of Anti-PSA Monoclonal Antibodies with Recombinant Human Kallikrein-2. Tumor Biology, 1999, 20, 35-37.	1.8	5
14	Prostate-specific antigen. Seminars in Cancer Biology, 1999, 9, 83-93.	9.6	156
15	Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific Antigen. Tumor Biology, 1999, 20, 1-12.	1.8	69
16	Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clinical Chemistry, 1999, 45, 814-21.	3.2	19
17	The clinical importance of free prostateâ€specific antigen (PSA). Current Opinion in Urology, 1998, 8, 393-399.	1.8	11
18	Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clinical Chemistry, 1998, 44, 2471-9.	3.2	18

#	Article	IF	CITATIONS
19	Activation of Type IV Procollagenases by Human Tumor-associated Trypsin-2. Journal of Biological Chemistry, 1997, 272, 21067-21074.	3.4	172
20	Prostate-specific antigen forms a complex with and cleaves $\hat{l}\pm 1$ -protease inhibitor in vitro. , 1997, 33, 87-96.		42
21	Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. British Journal of Cancer, 1996, 74, 568-572.	6.4	27
22	Significance of free and bound prostate-specific antigen. Endocrine-Related Cancer, 1996, 3, 191-197.	3.1	3
23	Serum complex of trypsin 2 and (alpha)(sub 1) antitrypsin as diagnostic and prognostic marker of acute pancreatitis: clinical study in consecutive patients. BMJ: British Medical Journal, 1996, 313, 333-337.	2.3	77
24	Complex formation between PSA isoenzymes and protease inhibitors. Journal of Urology, 1996, 155, 1099-103.	0.4	18
25	Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clinical Chemistry, 1995, 41, 182-186.	3.2	69
26	Standardization of PSA determinations. Scandinavian Journal of Clinical and Laboratory Investigation, 1995, 55, 45-51.	1.2	17
27	Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clinical Chemistry, 1995, 41, 1567-1573.	3.2	147
28	Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clinical Chemistry, 1995, 41, 1567-73.	3.2	46
29	Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clinical Chemistry, 1994, 40, 1761-1765.	3.2	43
30	Serum concentrations of prostate specific antigen and its complex with $\hat{l}\pm 1$ -antichymotrypsin before diagnosis of prostate cancer. Lancet, The, 1994, 344, 1594-1598.	13.7	248
31	Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clinical Chemistry, 1994, 40, 1761-5.	3.2	9
32	Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clinical Chemistry, 1993, 39, 2098-2103.	3.2	143
33	Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clinical Chemistry, 1993, 39, 2098-103.	3.2	21
34	A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Research, 1991, 51, 222-6.	0.9	717